Replies to post #1931 on ChromaDex Corp. (CDXC)

[DavenCT]

Here's the kind of info that's confidential. The asterisk-in-brackets in the actual document displays in this post as a bullet and replaces the name or type of product P&G are considering.

2.1.
PROJECT. The PARTIES will collaborate on the project, including key milestones and success criteria, set forth in Schedule 2.1 (“PROJECT”), which is expected to result in the development of STABLE NR and/or PRODUCTs intended for application in the COLLABORATION FIELD. The PARTIES may amend Schedule 2.1 by mutual agreement from time to time pursuant to Paragraph 11.4 (Entire Agreement / Amendment).

2.1.1.
Summary of the PROJECT. The PROJECT generally relates to the identification and use of STABLE NR in P&G’s consumer products for the

.

and

6.3.
Purchase Requirements. In the event a) sampling in Paragraph 6.1 (Sampling) and Paragraph 6.2 (Sampling Inventions) results in any creative idea, design development, invention, know-how, or work result (whether patentable or not patentable); b) there is no commercial agreement between the PARTIES for the purchase of NR or STABLE NR by P&G from COLLABORATION PARTNER; and c) if P&G launches a

product containing NR or STABLE NR within 2 years from the date of Termination of this JDA; P&G will purchase its requirements for NR for use either by itself or in the preparation of STABLE NR in connection with

from COLLABORATION PARTNER at COLLABORATION PARTNER’S MFN PRICING for a period of or 3 years from the date of the first retail sale of any such PRODUCT.


Here's the link to the doc: https://www.sec.gov/Archives/edgar/data/1386570/000141588916005140/cdxc_ex10-44.htm


As far as I can tell, our company is just protecting itself and doesn't want to spill-the-beans on some product that others might create on their own. P&G can safely work on this new or improved existing product without competitors looking over their shoulders.

I think the company is on the level and is working diligently to build itself into something greater. If the next drug trial provides validating evidence of the efficacy of the Niagen, then we're off to the races. With the possibly crooked board member removed, the company wants to present itself as the real deal- not a pump-and-dump or a 'rest-home' for mediocre board members. On dips, I'm accumulating again.

[exlud]

I think these guys are moving in the right direction, but it's...odd. I'd love to know who "Customer C" is, and I kind of wonder if that is tied in with the ct order. The recent offering of just over a million shares was done to erase a boatload of debt. More shares out, but less debt, and they did a 1:3 split in April. The prospectus also has a statement that essentially says "we just dumped a million shares on you, we might do it again". Kind of a boilerplate statement, but it's there.
Long story short, I have a LOT of reading to do before I can see all of the bigger picture here.